H.C. Wainwright analyst Douglas Tsao lowered the firm’s price target on Dare Bioscience to $6 from $7 and keeps a Buy rating on the shares post the Q3 report. Due to challenging capital markets conditions, the company will likely need to raise funds at lower prices than previously assumed, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DARE:
- Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update
- Dare Bioscience evaluating wide range of financing opportunities
- Dare Bioscience reports Q3 revenue $1M, consensus $430,000
- Dare Bioscience announces data from Phase 2b RESPOND study
- Daré Bioscience Announces Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women and Proposed Endpoints and Patient Population for Phase 3 Program